Login / Signup

Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.

Chi ZhangJiawen LiZhao WuHe WangChengli QueHong ZhaoGuiqiang Wang
Published in: Trials (2020)
Protocol version number 3.0, 10th April 2020. The recruitment has not yet started. Actual Study Start Date: April 1, 2020 Estimated Primary Completion Date: June 1, 2020 Estimated Study Completion Date: December 1, 2020 TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT04334265. Registered on 3 April 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Keyphrases
  • open label
  • randomized controlled trial
  • coronavirus disease
  • phase iii
  • phase ii
  • clinical trial
  • double blind
  • study protocol
  • early onset
  • squamous cell carcinoma
  • phase ii study
  • placebo controlled